<DOC>
	<DOCNO>NCT00900744</DOCNO>
	<brief_summary>The investigator plan examine endoxifen 4-OH-Tam function tamoxifen dose patient genetic CYP2D6 polymorphism . The investigator also plan investigate genetic variation metabolism tamoxifen .</brief_summary>
	<brief_title>A Pilot Study Varying Doses Tamoxifen Setting Genetic Polymorphisms CYP2D6</brief_title>
	<detailed_description>Endocrine therapy proven extremely effective therapy breast cancer . For woman hormone-receptor-positive tumor , tamoxifen give little two year result statistically significant recurrence survival benefit . The benefit increase duration treatment increase , 5 year , among woman treat five year , tamoxifen result 46 percent annual reduction recurrence rate 28 percent annual reduction death rate . This mean half recurrence one fourth death year prevent tamoxifen treatment . However , despite initial successful response , many patient tamoxifen relapse die progressive disease . Consequently , tamoxifen resistance remain major clinical problem management breast cancer . Tamoxifen metabolize cytochrome P450 2D6 ( CYP2D6 ) potent metabolites 4-hydroxy-tamoxifen ( 4-OH-TAM ) 4-hydroxy-N-desmethyltamoxifen ( endoxifen ) . Variations metabolic capacity enzyme show independent predictor breast cancer relapse death . To date , study correlate tamoxifen dos CYP2D6 genotype status associate tamoxifen dose endoxifen 4-OH-tamoxifen . We plan examine endoxifen 4-OH-Tam function tamoxifen dose patient genetic CYP2D6 polymorphism . We also plan investigate genetic variation metabolism tamoxifen . The possible identification gene variant alter tamoxifen 's metabolism may improve initial dose selection therefore optimize treatment outcome future . In addition examine polymorphism CYP2D6 , examine gene may influence metabolism medication .</detailed_description>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Women take tamoxifen 20mg day Tamoxifen use &gt; 90 day . Use accept barrier form contraception . Patients exclude pregnant lactating ; pre menopausal , patient document negative pregnancy test use accept barrier form contraception . Patients exclude medical history Hepatitis B . Hepatitis C HIV Patients exclude use Tobacco Patients exclude medical history hereditary hemochromatosis Patients exclude elevate AST ( SGOT ) , ALT ( SGPT ) , Biliribin Alkaline Phosphate Defined great 2 1/2 time upper limit normal Patients exclude treated chemotherapy Patients exclude take follow oral medication , potent CYP2D6 inhibitor : Fluoxetine ( Prozac ) Miconazole ( Monistat ) Paroxetine ( Paxil ) Quinidine Ritonavir ( Norvir ) Atorvastatin ( Lipitor ) Carvedilol ( Coreg ) Clarithromycin ( Biaxin ) Dipyridamole ( Persantine ) Erythromycin Grapefruit Juice Itraconazole ( Sporanox ) Ketoconazole Mefloquine Nelfinavir ( Viracept ) Nicardipine ( Cardene ) Nilotinib Propranolol ( Inderal ) Ranolazine ( Ranexa ) Saquinavir ( Invirase ) Verapamil CoveraHS Warfarin ( Coumadin ) Chlorpromazine ( Thorazine ) Cinacalcet ( Sensipar ) Delavirdine ( Rescriptor )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Tamoxifen</keyword>
	<keyword>Breast Cancer</keyword>
</DOC>